Physicians treating Alzheimer’s patients discussed why they’re hesitant to prescribe lecanemab (Leqembi). (Reuters)
Researchers reviewed the role of neurofilament proteins in multiple sclerosis (MS), Alzheimer’s disease, frontotemporal dementia, amyotrophic lateral sclerosis, stroke and cerebrovascular disease, traumatic brain injury, and Parkinson’s disease. (Nature Reviews Neurology)
Mobile and wearable sensor data helped monitor MS disability and fatigue and distinguished patients from healthy controls. (NPJ Digital Medicine)
Subcutaneous injection of ocrelizumab (Ocrevus) showed results consistent with IV infusion at 48 weeks in MS, Roche said.
The NeuroRights Foundation called for better privacy practices to safeguard brain data in the consumer neurotechnology market.
A small study suggested preoperative cognitive training may reduce postoperative delirium incidence in people undergoing coronary artery bypass grafting. (JAMA Network Open)
An exploratory analysis of phase II data suggested that investigational prasinezumab, a monoclonal antibody that binds aggregated alpha-synuclein, slowed motor progression in rapidly progressing early-stage Parkinson’s disease. (Nature Medicine)
People who had cognitively stimulating occupations during their 30s, 40s, 50s, and 60s had a lower risk of mild cognitive impairment and dementia when they were over 70. (Neurology)
The investigational antisense oligonucleotide GTX-102 showed clinical benefit in a phase I/II study of Angelman syndrome, Ultragenyx announced.
Based on phase II trial data, Sage Therapeutics ended its study of dalzanemdor for mild cognitive impairment in Parkinson’s disease.
Meanwhile, adjunctive tavapadon improved motor outcomes for Parkinson’s patients in a phase III study, Cerevel Therapeutics said.
Oral atogepant (Qulipta) became the first calcitonin gene-related peptide blocker recommended by health authorities in England for chronic and episodic migraine prevention.
Please enable JavaScript to view the